GT Biopharma Inc (GTBP)

[wasdeafonce]

First, I think that the regulatory avenue will be done in the European space due to the new rules governing Adaptive Licensing. The FDA will be more likely to allow a study done here with the credentials the EU study will bring. Second, one needs to look at the sub-licensing agreement with MCIT. It appears that OXIS will be licensing this out, whether or not it's to a big dog is the question, and the one we are contemplating.